Sarizotan
Pre-clinicalTerminated 0 watching 0 views this week💤 Quiet
23
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Neuroleptic-induced Tardive Dyskinesia
Conditions
Neuroleptic-induced Tardive Dyskinesia
Trial Timeline
Dec 1, 2004 → Mar 1, 2008
NCT ID
NCT00310661About Sarizotan
Sarizotan is a pre-clinical stage product being developed by Merck for Neuroleptic-induced Tardive Dyskinesia. The current trial status is terminated. This product is registered under clinical trial identifier NCT00310661. Target conditions include Neuroleptic-induced Tardive Dyskinesia.
Hype Score Breakdown
Clinical
5
Activity
2
Company
10
Novelty
2
Community
1
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00310661 | Pre-clinical | Terminated |
Competing Products
1 competing product in Neuroleptic-induced Tardive Dyskinesia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Gabapentin | Pfizer | Phase 3 | 76 |